Fangzhou Achieves 2024 National High-Tech Enterprise Recognition Driving Healthcare Innovation
In a major achievement signifying its commitment to innovation within the healthcare sector, Beijing Fangyixing Information Technology Co., Ltd., a key subsidiary of Fangzhou Inc., has been awarded the prestigious designation of a National High-Tech Enterprise for 2024. This recognition is not merely an accolade but a testament to the company’s ongoing efforts in leading advancements in AI-powered healthcare solutions. The certification was granted in a joint effort by the Beijing Science and Technology Commission, the Beijing Finance Bureau, and the Beijing Municipal Tax Service, highlighting Fangyixing's exemplary competencies in core intellectual property, effective commercialization of scientific developments, and comprehensive R&D management practices.
Dr. Xie Fangmin, who serves as the founder, chairman, and CEO of Fangzhou, expressed pride in this honor, stating that it reflects their long-term commitment to research and development. This designation empowers the organization to further invest in AI innovations that drive their H2H Smart Healthcare Ecosystem. Dr. Xie elaborated that Fangzhou will intensify collaboration with various industry pioneers, aiming to transform cutting-edge research into practical healthcare solutions that can significantly improve patient outcomes.
The financial performance of Fangzhou underscores the impact of its innovative strategy. In its first annual report post-IPO, the company noted a solid growth trajectory with a reported 11.2% year-over-year revenue increase, amounting to RMB 2.707 billion for 2024. Additionally, the adjusted net profit saw an astonishing rise of 139% compared to the previous year, totaling RMB 17.1 million. This robust financial performance is largely attributed to the company’s steadfast commitment to investing in AI-enabled technologies that enhance operational efficiency and create sustainable business value.
Fangzhou aims to further revolutionize its healthcare offerings by deploying advanced AI models such as DeepSeek-V3, alongside exciting partnerships with major companies like Tencent Health and Tencent Cloud. These collaborations are designed to accelerate the development and implementation of AI-driven healthcare services, aligning with Fangzhou’s strategic vision to enhance overall user experience for both patients and healthcare providers.
Fangzhou Inc., listed under the stock code 06086.HK, represents a formidable presence in China’s healthcare landscape. As of December 31, 2024, the company boasted approximately 49.2 million registered users and collaborated with around 223,000 medical professionals. Its focus on customized medical care and precision medicine solutions places it at the forefront of the healthcare technology sector in China, making significant strides to meet the increasing demands of modern healthcare.
The National High-Tech Enterprise status is regarded as one of the highest recognitions for technological excellence in China, reserved for companies demonstrating significant innovation in strategic sectors. To qualify for this designation, enterprises must showcase consistent R&D investments, successfully translate proprietary technologies into market applications, and achieve a leading domestic or international presence in transforming research into real-world results. As such, this award not only validates Fangzhou's scientific capabilities but also solidifies its role as an innovator in a highly competitive technological environment.
As Fangzhou continues to push the boundaries of technological advancement in healthcare, the implications of its innovations are likely to resonate throughout the industry, bringing forth impactful solutions that facilitate long-term patient care and management, ultimately setting new standards for healthcare practices globally. For further updates and information, please visit Fangzhou's investor relations online platform.
Dr. Xie Fangmin, who serves as the founder, chairman, and CEO of Fangzhou, expressed pride in this honor, stating that it reflects their long-term commitment to research and development. This designation empowers the organization to further invest in AI innovations that drive their H2H Smart Healthcare Ecosystem. Dr. Xie elaborated that Fangzhou will intensify collaboration with various industry pioneers, aiming to transform cutting-edge research into practical healthcare solutions that can significantly improve patient outcomes.
The financial performance of Fangzhou underscores the impact of its innovative strategy. In its first annual report post-IPO, the company noted a solid growth trajectory with a reported 11.2% year-over-year revenue increase, amounting to RMB 2.707 billion for 2024. Additionally, the adjusted net profit saw an astonishing rise of 139% compared to the previous year, totaling RMB 17.1 million. This robust financial performance is largely attributed to the company’s steadfast commitment to investing in AI-enabled technologies that enhance operational efficiency and create sustainable business value.
Fangzhou aims to further revolutionize its healthcare offerings by deploying advanced AI models such as DeepSeek-V3, alongside exciting partnerships with major companies like Tencent Health and Tencent Cloud. These collaborations are designed to accelerate the development and implementation of AI-driven healthcare services, aligning with Fangzhou’s strategic vision to enhance overall user experience for both patients and healthcare providers.
Fangzhou Inc., listed under the stock code 06086.HK, represents a formidable presence in China’s healthcare landscape. As of December 31, 2024, the company boasted approximately 49.2 million registered users and collaborated with around 223,000 medical professionals. Its focus on customized medical care and precision medicine solutions places it at the forefront of the healthcare technology sector in China, making significant strides to meet the increasing demands of modern healthcare.
The National High-Tech Enterprise status is regarded as one of the highest recognitions for technological excellence in China, reserved for companies demonstrating significant innovation in strategic sectors. To qualify for this designation, enterprises must showcase consistent R&D investments, successfully translate proprietary technologies into market applications, and achieve a leading domestic or international presence in transforming research into real-world results. As such, this award not only validates Fangzhou's scientific capabilities but also solidifies its role as an innovator in a highly competitive technological environment.
As Fangzhou continues to push the boundaries of technological advancement in healthcare, the implications of its innovations are likely to resonate throughout the industry, bringing forth impactful solutions that facilitate long-term patient care and management, ultimately setting new standards for healthcare practices globally. For further updates and information, please visit Fangzhou's investor relations online platform.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.